Poolbeg Pharma advancing products, platforms and opportunities (VIDEO)

Poolbeg Pharma (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss interim results for the six months to 30th June 2022.

Jeremy talks us through the financial and operational highlights, the progress being made across the pipeline and with strong financial resources available how he sees the outlook.

Poolbeg Pharma plc (LON: POLB) is a clinical stage infectious disease pharmaceutical company, with a clinical model which enables them to develop multiple products faster and more cost effectively than a traditional biotech model.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Share on twitter
Share on linkedin

More articles like this

What to know about RSV

Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. Prevent RSV Protect your child from

The role of AI in therapeutic research

The role of artificial intelligence (AI) in therapeutic research has become increasingly prominent in recent years, with the potential to revolutionize drug discovery, testing, and personalized medicine. This transformative technology is poised to reshape the future of healthcare,

What role is AI/ML playing in drug development?

Artificial Intelligence (AI) and Machine Learning (ML) can be described as a branch of computer science, statistics, and engineering that uses algorithms or models to perform tasks and exhibit behaviors such as learning, making decisions, and making predictions.

How AI is transforming drug discovery

The pharmaceutical industry is continually seeking novel approaches to create and identify effective treatments that cater to medical requirements. The procedure of discovering drugs is a daunting process that demands significant resources. Recently, this method has undergone significant

The future of AI in the pharmaceutical industry

Artificial intelligence is revolutionising the pharmaceutical and biotechnology industries. Its unparalleled power to make predictions based on large data sets is advancing understanding of diseases, improving diagnostic speed and accuracy, accelerating drug discovery, and improving clinical trials. AI’s

AI and Drug Discovery

The use of artificial intelligence (AI) in drug discovery is revolutionizing the pharmaceutical industry. AI-driven drug discovery has the potential to reduce the time and cost of drug development, while also improving the accuracy and efficacy of new treatments. However,

Professor Siobhan McClean on Vaccine Candidates

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma publishes Annual Results

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the period ended 31 December 2022 and the notice of Annual

Revolutionising drug discovery

Renowned futurist Ray Kurzweil has predicted a seismic shift in the balance of power between man and machine: a momentous occasion he calls “the singularity”. This prophecy foresees a time, likely to occur around 2045, when computers will

The age of AI has begun

Health I see several ways in which AIs will improve health care and the medical field. For one thing, they’ll help health-care workers make the most of their time by taking care of certain tasks for them—things like

Poolbeg Pharma continues expansion and diversification of pipeline

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF) a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, has announced its audited results for the year ended 31 December 2022. Financial & Corporate Highlights –       Well

New results for severe influenza and inflammatory conditions

Poolbeg Pharma, an infectious disease-focused biopharmaceutical company, has announced data from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from

Poolbeg Pharma releases positive data from influenza trial

Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral infections. POLB 001 showed success in reducing multiple markers

Poolbeg Pharma granted patent by USPTO for POLB 001

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF),  a leading infectious disease focused biopharmaceutical company, has announced that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and Trademark Office (USPTO) for methods of treating hypercytokinaemia

No more posts to show